San Diego, CA, United States of America

Ravi Ramenani

This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Zafrens, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ravi Ramenani: Innovator in Drug Discovery Technologies

Introduction

Ravi Ramenani is a notable inventor based in San Diego, CA, who has made significant contributions to the field of drug discovery. His innovative work focuses on the development of unique technologies that enhance the efficiency and accuracy of assays used in biomedical research.

Latest Patents

Ravi Ramenani holds a patent for "Perturbation beads for use in assays." This patent discloses uniquely labeled perturbation beads that can be used alone or in combination with a capture bead. These perturbation beads are particularly useful in drug discovery, especially in assays conducted in a mapped assay device. The uniquely labeled perturbation bead allows for correlating the sequence of nucleic acids and other components from a lysed cell to the specific examination area where the nucleic acid was retrieved. He has 1 patent to his name.

Career Highlights

Throughout his career, Ravi has worked with several prominent companies, including Zafrens, Inc. and 10X Genomics, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of drug discovery.

Collaborations

Ravi has collaborated with talented individuals such as David Milliken and Maina Ndungu, contributing to a dynamic work environment that fosters innovation and creativity.

Conclusion

Ravi Ramenani's contributions to drug discovery through his patented technologies highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in biomedical research and assay development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…